Help on the way for hepatitis C patients who also have kidney failure

Hepatitis C has been enough of a problem, but there are also a dozens of Israelis who also have kidney failure and undergo kidney dialysis as well.

April 26, 2014 22:12
1 minute read.

A model of human kidneys.. (photo credit: MCT)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Hepatitis C has been enough of a problem, but there are also a dozens of Israelis who also have kidney failure and undergo kidney dialysis as well.

Dr. Yoav Lurie of the capital’s Shaare Zedek Medical Center, along with liver experts at Sheba Medical Center at Tel Hashomer, Tel Aviv Sourasky Medical Center and Rambam Medical Center and Carmel Medical Center in Haifa are about to test the Merck drugs MK-5172 and MK-8742 on their kidney failure patients (or those who have undergone kidney transplants but the new organs do not function well enough) who also have hepatitis C.

“Such people are usually very fragile because of their multiple conditions and most of them have not been eligible for current medications because these could worsen their general and kidney conditions,” said Lurie.

“But with the development of the experimental new pills, we are about to test one of them and are in the process of reviewing possible candidates. We can accept only those who are in reasonable condition.” The international trial will take up to six months, said Lurie, but “we are very hopeful, because in previous cases, no side effects were observed in patients with normal kidney functions.”

Potential recipients with both conditions are invited to contact him at or or to call the unit at (02) 6555035. Those not near Jerusalem can go to the liver clinics at any of the other four medical centers.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice